Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.

Saved in:
Bibliographic Details
Title: Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
Authors: Zanotto-Filho, Alfeu1,2, Rajamanickam, Subapriya1, Loranc, Eva1, Masamsetti, V. Pragathi1, Gorthi, Aparna1,3, Romero, July Carolina1,3, Tonapi, Sonal1,3, Gonçalves, Rosangela Mayer2, Reddick, Robert L.4, Benavides, Raymond5, Kuhn, John4,5, Chen, Yidong6, Bishop, Alexander J.R.1,3 bishopa@uthscsa.edu
Source: Cancer Letters. Jul2018, Vol. 425, p101-115. 15p.
Database: Academic Search Ultimate
Description
ISSN:03043835
DOI:10.1016/j.canlet.2018.03.037